1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Slovakia Pharmaceuticals and Healthcare Report Q3 2015

Slovakia Pharmaceuticals and Healthcare Report Q3 2015

  • June 2015
  • -
  • Business Monitor International
  • -
  • 118 pages

Includes 3 FREE quarterly updates

BMI View: Eurozone recovery and an improving domestic economic outlook will provide a boost to healthcare expenditure in Slovakia in the short-term. Over the longer term, we expect healthcare spending to accelerate given Slovakia's ageing population and burden of chronic diseases. With public finances on firmer footing and a centre-left government promising more generous social spending, multinational drugmakers and medical device companies can expect to see growth in revenues from Slovakia.

Headline Expenditure Projections
- Pharmaceuticals: EUR1.85bn (USD2.46bn) in 2014 to EUR1.91bn (USD2.30bn) in 2015; +3.5% in local currency terms and -6.6% in US dollar terms.
- Healthcare: EUR6.13bn (USD8.15bn) in 2014 to EUR6.37bn (USD7.64bn) in 2015; 3.9% in local currency terms and -6.2% in US dollar terms.

Table Of Contents

Slovakia Pharmaceuticals and Healthcare Report Q3 2015
BMI Industry View 7
SWOT 9
Politics 11
Economic 12
Operational Risk 13
Industry Forecast 15
Pharmaceutical Market Forecast 15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovakia 2011-2019) 16
Healthcare Market Forecast 17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2011-2019) 19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2011-2019) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2011-2019) 20
Prescription Drug Market Forecast 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovakia 2011-2019) 23
Patented Drug Market Forecast 24
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovakia 2011-2019) 25
Generic Drug Market Forecast 26
Table: Members Of GENAS, 2015 28
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Slovakia 2011-2019) 28
OTC Medicine Market Forecast 29
Table: Leading Prescription Medicines In Slovakia, By 2011 Volume 30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovakia 2011-2019) 31
Pharmaceutical Trade Forecast 32
Table: Pharmaceutical Trade Data And Forecasts (Slovakia 2013-2019) 34
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovakia 2013-2019) 34
Key Risks To BMI's Forecast Scenario 35
Macroeconomic Forecasts 36
Economic Analysis 36
Table: Economic Activity (Slovakia 2010-2019) 43
Industry Risk Reward Indices 44
Central And Eastern Europe Risk/Reward Index 44
Slovakia Risk/Reward Index 50
Rewards 50
Risks 50
Market Overview 52
Industry Trends And Developments 54
Epidemiology 54
Table: Main Causes Of Mortality And Morbidity In Slovakia 55
Communicable Diseases 55
Healthcare Sector 56
Table: Healthcare Resources (Slovakia 2009-2014) 57
Table: Healthcare Personnel (Slovakia 2009-2014) 58
Table: Healthcare Activity (Slovakia 2009-2014) 58
Recent Healthcare Sector Developments 58
Health Insurance 60
Private Health Insurance 61
Recent Health Insurance Developments 62
Research And Development 64
Table: Members Of BITCET, 2011 65
Table: Members Of SLOVBIOTECH, 2010 66
Clinical Trials 66
Regulatory Development 68
Regulatory Regime 68
Pharmaceutical Promotion And Advertising 69
Marketing Authorisation Regime 70
Intellectual Property Issues 71
Pricing Regime 72
Table: Indexed Price Build-Up For Prescription And Non-Prescription Medicines In Slovakia 73
Reimbursement Regime 74
Competitive Landscape 78
Research-Based Industry 78
Table: Members Of SAFS, 2012 78
Generic Drugmakers 78
Table: Registered Pharmaceutical Manufacturers 79
Pharmaceutical Distribution 80
Table: ADL Members, 2012 (Manufacturers, unless otherwise indicated) 81
Pharmaceutical Retail 81
Company Profile 84
Roche 84
Biotika 86
HBM Pharma 88
Imuna Pharma 91
GlaxoSmithKline 93
Sanofi 95
Pfizer 98
Novartis 100
Merck and Co 102
Zentiva (Sanofi) 104
Demographic Forecast 107
Table: Population Headline Indicators (Slovakia 1990-2025) 108
Table: Key Population Ratios (Slovakia 1990-2025) 108
Table: Urban/Rural Population and Life Expectancy (Slovakia 1990-2025) 109
Table: Population By Age Group (Slovakia 1990-2025) 109
Table: Population By Age Group % (Slovakia 1990-2025) 110
Glossary 112
Methodology 114
Pharmaceutical Expenditure Forecast Model 114
Healthcare Expenditure Forecast Model 114
Notes On Methodology 115
Risk/Reward Index Methodology 116
Index Overview 117
Table: Pharmaceutical Risk/Reward Index Indicators 117
Indicator Weightings 118

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

  • $ 6 995
  • Industry report
  • February 2016
  • by GBI Research

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes Summary The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 ...

Opportunity in the Indian Pharmaceutical Market - 2016; Market size, Market share, Market landscape, Market trend analysis, Growth drivers, Future opportunity, Future forecast

Opportunity in the Indian Pharmaceutical Market - 2016; Market size, Market share, Market landscape, Market trend analysis, Growth drivers, Future opportunity, Future forecast

  • $ 5 750
  • Industry report
  • April 2016
  • by Feedback Business Consulting

This report provides an insight into the Indian Pharmaceutical current market scenario, structure and practices. In depth market scenario includes; - Current market size estimates, including domestic market, ...

Omega 3 PUFA Market: Type (DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), ALA (Alpha-linoleic acid)) Source (Marine, Plant) Form (Oils, Capsules, Powder) Application (Dietary Supplements, Pharmaceuticals, Infant Foods, F&B)-Forecast(2015-2020)

Omega 3 PUFA Market: Type (DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), ALA (Alpha-linoleic acid)) Source (Marine, Plant) Form (Oils, Capsules, Powder) Application (Dietary Supplements, Pharmaceuticals, Infant Foods, F&B)-Forecast(2015-2020)

  • $ 5 250
  • Industry report
  • February 2016
  • by Industry ARC

Omega-3 fatty acids are polyunsaturated fatty acids which have potential health benefits and are essential for increasing metabolic rate. Omega-3 PUFA ingredients are used to manufacture products that ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.